Hoth Therapeutics Announces Major Advancements For HT-KIT, Filing Amended Claims For Enhanced IP Protection And Initiating GLP-Compliant Preclinical Toxicity Study To Support Regulatory Filings For Its ASO Cancer Drug Candidate Targeting Allergic Inflammation And Mast Cell-Related Diseases

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases, today announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide (ASO) cancer fighting drug candidate, HT-KIT.

The Company has filed amended claims with the U.S. Patent and Trademark Office for its lead ASO technology targeting MS4A6A and FcεRIβ—genes implicated in allergic inflammation and mast cell-related diseases. These refined claims enhance intellectual property protection for HT-KIT and further position it as a novel therapeutic platform with broad clinical potential, including use in treating conditions such as anaphylaxis, mastocytosis, and allergic asthma.

In parallel, Hoth has initiated a GLP-compliant 4-week intravenous toxicity study with a 14-day recovery period in C57BL/6 mice. This preclinical study, conducted in partnership with OnTargetx R&D Inc. and ITR Laboratories, is designed to evaluate the safety profile of HT-KIT in support of upcoming regulatory filings. The study will include multiple dose groups, detailed pathology assessments, and pharmacokinetic profiling.